Joseph J. Ferra Jr. - 16 Mar 2023 Form 4 Insider Report for Elevation Oncology, Inc. (ELEV)

Role
INTERIM CEO & CFO
Signature
/s/ Robert Yang, Attorney-in-Fact
Issuer symbol
ELEV
Transactions as of
16 Mar 2023
Net transactions value
-$11,217
Form type
4
Filing time
20 Mar 2023, 16:21:08 UTC
Previous filing
17 Feb 2023
Next filing
21 Jun 2023
SEC
View on sec.gov

Transactions Table

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Ownership Footnotes
transaction ELEV Common Stock Options Exercise +12,563 +27% 59,295 16 Mar 2023 Direct F1
transaction ELEV Common Stock Tax liability $11,217 -4,773 -8% $2.35 54,522 16 Mar 2023 Direct

Derivative Securities (e.g., puts, calls, warrants, options, convertible securities)

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Underlying Class Amount Exercise Price Ownership Footnotes
transaction ELEV Restricted Stock Unit Options Exercise $0 -12,563 -10% $0.000000 113,059 16 Mar 2023 Common Stock 12,563 Direct F1, F2, F3
* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Explanation of Responses:

Id Content
F1 Each restricted stock unit ("RSU") represents a contingent right to receive one share of the Issuer's common stock.
F2 25% of the RSUs vested on June 16, 2022, and the remainder will vest in quarterly installments thereafter, subject to the Reporting Person's continued service to the Issuer on each vesting date.
F3 The RSUs do not expire; they either vest or are canceled prior to the vesting date.